Literature DB >> 23212831

CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.

Kin-Fai Cheung1, Junhong Zhao, Ying Hao, Xiaoxing Li, Anson W Lowe, Alfred S L Cheng, Joseph J Y Sung, Jun Yu.   

Abstract

BACKGROUND: Previous reports from these authors found that activation of peroxisome proliferator-activated receptor gamma (PPARγ) suppressed hepatocellular carcinoma (HCC). This study sought to identify the molecular target of PPARγ and characterize its antitumor effect in HCC.
METHODS: Optimal PPARγ binding activity was obtained using the PPARγ agonist rosiglitazone (100 μM) as determined by enzyme-linked immunosorbent assay. Under PPARγ activation, 114 PPARγ downstream targets associated with cancer development were identified by oligonucleotide microarray and Gene Ontology analysis. Among them, Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 (CITED2) was the most prominent PPARγ-bound target, as determined by chromatin immunoprecipitation-polymerase chain reaction.
RESULTS: CITED2 messenger RNA and protein was significantly down-regulated in primary HCCs compared with their adjacent nontumor tissues. PPARγ induced expression of CITED2 in HCC cell lines after adenovirus-PPARγ transduction. The biological function of CITED2 was evaluated by loss- and gain-of-function assays. CITED2 knockdown in the hepatocyte cell line LO2 and HCC cell line Hep3B significantly increased cell viability and clonogenicity, and promoted G1 -S phase transition in both cell lines. In contrast, ectopic expression of CITED2 in HepG2 and BEL7404 HCC cell lines significantly suppressed cell growth. The tumor suppressive effect of CITED2 was associated with up-regulation of cyclin-dependent kinase inhibitors p15(INK4B) , p21(Wat1/Cip1) , p27(Kip1) , antiproliferative regulator interferon alpha 1, proapoptotic mediators including tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), TNFRSF25, caspase-8, granzyme A, and the tumor suppressor gene maspin. CITED2 was also associated with the down-regulation of cell cycle regulator cyclin D1, oncogene telomerase reverse transcriptase, and proinvasion/metastasis gene matrix metallopeptidase 2.
CONCLUSIONS: CITED2 is a direct effector of PPARγ for tumor suppression. Cancer 2013. © 2012 American Cancer Society.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212831     DOI: 10.1002/cncr.27865

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 2.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

3.  Cited2, a transcriptional modulator protein, regulates metabolism in murine embryonic stem cells.

Authors:  Qiang Li; Parvin Hakimi; Xia Liu; Wen-Mei Yu; Fang Ye; Hisashi Fujioka; Syed Raza; Eswar Shankar; Fangqiang Tang; Sally L Dunwoodie; David Danielpour; Charles L Hoppel; Diana L Ramírez-Bergeron; Cheng-Kui Qu; Richard W Hanson; Yu-Chung Yang
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

4.  miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop.

Authors:  Y Zhang; J Dai; H Deng; H Wan; M Liu; J Wang; S Li; X Li; H Tang
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640

5.  Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.

Authors:  I Walter; U Schulz; M Vogelhuber; K Wiedmann; E Endlicher; F Klebl; R Andreesen; W Herr; L Ghibelli; C Hackl; R Wiest; A Reichle
Journal:  Med Oncol       Date:  2017-11-02       Impact factor: 3.064

6.  MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma.

Authors:  Zhikui Liu; Yufeng Wang; Changwei Dou; Liankang Sun; Qing Li; Liang Wang; Qiuran Xu; Wei Yang; Qingguang Liu; Kangsheng Tu
Journal:  J Exp Clin Cancer Res       Date:  2018-03-06

Review 7.  CITED2 and the modulation of the hypoxic response in cancer.

Authors:  Mónica T Fernandes; Sofia M Calado; Leonardo Mendes-Silva; José Bragança
Journal:  World J Clin Oncol       Date:  2020-05-24

8.  Applying NGS Data to Find Evolutionary Network Biomarkers from the Early and Late Stages of Hepatocellular Carcinoma.

Authors:  Yung-Hao Wong; Chia-Chou Wu; Chih-Lung Lin; Ting-Shou Chen; Tzu-Hao Chang; Bor-Sen Chen
Journal:  Biomed Res Int       Date:  2015-08-20       Impact factor: 3.411

9.  High fidelity copy number analysis of formalin-fixed and paraffin-embedded tissues using Affymetrix Cytoscan HD chip.

Authors:  Yan P Yu; Amantha Michalopoulos; Ying Ding; George Tseng; Jian-Hua Luo
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

Review 10.  Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma.

Authors:  Hui-Tzu Hsu; Chin-Wen Chi
Journal:  J Hepatocell Carcinoma       Date:  2014-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.